Physician profile
Bailey Stokes
NPI 1699441980
$8,203.59
in general payments reported to CMS, 2019-2025
55 companies · $3,167 in 2025
The $3,167 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,066 · 2024: $2,971 · 2025: $3,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,852 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,852.11 |
| Education | $351.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,145.46 | 2023-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $969.50 | 2023-2025 | |
| Janssen Biotech, INC. | $574.40 | 2023-2025 | Erleada, Akeega, Talvey |
| Merck Sharp & Dohme LLC | $544.27 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $460.30 | 2023-2025 | |
| Lilly USA, LLC | $395.33 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals LP | $372.77 | 2023-2025 | Imfinzi, Calquence, Lynparza |
| Celgene Corporation | $327.18 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Glaxosmithkline, LLC. | $210.24 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Pharmaessentia USA Corporation | $193.58 | 2024-2025 | Besremi |
| Daiichi Sankyo INC. | $183.87 | 2024-2025 | Datroway, Enhertu, Injectafer |
| Incyte Corporation | $182.82 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| E.R. Squibb & Sons, L.L.C. | $168.95 | 2023-2025 | Opdivo |
| Puma Biotechnology, INC. | $146.96 | 2023-2025 | Nerlynx |
| Bayer Healthcare Pharmaceuticals INC. | $135.83 | 2023-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $134.69 | 2025 | Zoladex, Xermelo |
| Beone Medicines USA, INC. | $126.98 | 2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $125.21 | 2024-2025 | Polivy, Columvi, Lunsumio |
| Takeda Pharmaceuticals U.S.A., INC. | $121.01 | 2024-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Pfizer INC. | $115.24 | 2024-2025 | |
| Stemline Therapeutics INC. | $101.24 | 2023-2025 | Orserdu |
| Beigene USA, INC. | $96.92 | 2024-2025 | Brukinsa |
| Gilead Sciences, INC. | $93.71 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $93.06 | 2023-2024 | Monoferric, Cosela |
| Abbvie INC. | $83.28 | 2023-2025 | |
| Astellas Pharma US INC | $77.90 | 2024-2025 | Vyloy, Xtandi, Padcev |
| Adaptive Biotechnologies Corporation | $74.33 | 2023-2025 | Clonoseq |
| Rigel Pharmaceuticals, INC. | $73.25 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Ipsen Biopharmaceuticals, INC | $70.10 | 2024-2025 | Onivyde, Somatuline Depot |
| Apellis Pharmaceuticals, INC. | $69.70 | 2024-2025 | Empaveli |
| Caris Mpi, INC. | $67.08 | 2025 | Mi Cancer Seek |
| Genmab U.S., INC. | $65.64 | 2024-2025 | Tivdak, Epkinly |
| Alexion Pharmaceuticals, INC. | $54.45 | 2023-2025 | Ultomiris |
| Emd Serono, INC. | $51.91 | 2023-2025 | Bavencio |
| Karyopharm Therapeutics INC. | $48.82 | 2023-2025 | Xpovio |
| Array Biopharma INC | $40.62 | 2025 | Braftovi, Lorbrena, Mektovi |
| Regeneron Healthcare Solutions, INC. | $40.49 | 2023-2025 | Libtayo |
| Azurity Pharmaceuticals, INC. | $36.05 | 2025 | Danziten |
| G1 Therapeutics, INC. | $27.56 | 2023 | Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.22 | 2025 | |
| Geron Corporation | $24.19 | 2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $23.71 | 2024 | |
| Recordati_rare_diseases_inc. | $23.33 | 2024 | Sylvant |
| Alnylam Pharmaceuticals INC. | $21.26 | 2024 | Givlaari |
| Mirati Therapeutics, INC. | $19.70 | 2024 | Krazati |
| Sobi, INC | $19.59 | 2024 | |
| Amgen INC. | $19.12 | 2023 | Lumakras |
| Immunocore Limited | $18.46 | 2025 | Kimmtrak |
| Genzyme Corporation | $18.08 | 2023 | |
| Deciphera Pharmaceuticals INC. | $16.09 | 2024 | Qinlock |
| Tempus Ai, INC | $15.64 | 2024 | |
| Aveo Pharmaceuticals, INC. | $15.32 | 2023 | Fotivda |
| Invivyd INC | $15.05 | 2025 | Pemgarda |
| Seagen INC. | $14.99 | 2023 | Tukysa |
| Dendreon Pharmaceuticals LLC | $14.14 | 2025 | Provenge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.